ICU Medical, Inc. (ICUI) SEC Filings & Earnings Calls

Divestiture of IV Solutions business creates revenue gap in Vital Care segment, but overall growth is supported by other segments.

“Vital Care revenue declined 32% YoY due to the divestiture of IV Solutions business on May 1, 2025.”

Restructuring and integration execution risk

“Restructuring, strategic transaction and integration expenses were $ 21.3 million and $ 38.1 million for the three and six months ended June 30, 2026, respectively, as compared to $ 16.2 million and $ 32.9 million for the three and six months ended June 30, 2025, respectively.” · word for word

Tariff cost volatility

“For the three and six months ended June 30, 2026, tariff and duties (income) expense, net of ($ 8.0 ) million and $ 5.1 million, respectively, included $ 0.8 million and $ 1.9 million, respectively, typically grouped within standard COGS, and $ 10.1 million and $ 22.1 million, respectively, typically grouped within other COGS. The amounts typically grouped w” · word for word

Revenue decline due to IV Solutions divestiture; organic growth modest.

“GAAP revenue down 12%; organic up only 1%.”

Exposure to tariffs and supply chain disruptions.

“Forward-looking statements mention tariffs and supply chain risks.”

Tariff cost pressure

“Tariffs and duties expense (4) $13,142 $5,372”

Restructuring and integration risk

“Restructuring, strategic transaction and integration 16,801 16,697” · word for word

Revenue decline from IV Solutions sale

“Vital Care (1) $72,346 $172,176”

Italy medical device payback provision

“Italy medical device payback provision (1) $25,083 $24,597”

Field corrective action costs

“Field service corrective action (2) $26,363 $27,777”

Tariff Cost Exposure

“The Adjusted EBITDA and FCF results were adjusted by $4 million out of the $26 million of incremental tariff expense recognized by the Company during 2025 and by $18 million of the incremental $30 million of incremental tariffs paid by the Company during 2025, respectively.” · word for word

Revenue Decline from Joint Venture Deconsolidation

“Revenue $ 2,231.3 $ 2,382.0 (6.3) %” · word for word

No material risk; routine compensation plan extension.

“Amendment to Executive Severance Plan extending expiration date.”

Tariff impact on Costa Rican and Mexican manufacturing

“The most significant potential impact to us is the additional tariffs on Costa Rican and Mexican imports, which could result in a meaningful impact to our results of operations due to our manufacturing facilities in these countries.” · word for word

Product recall liabilities

“the costs associated with conducting and closing these or any other product recalls, including any liabilities we may incur, could have a material adverse effect on our business, financial condition and results of operations.” · word for word

Foreign currency exchange rate exposure

“Our operations may be adversely impacted by our exposure to risks related to foreign currency exchange rates.” · word for word

Patent expiration and intellectual property risks

“The loss of patent protection on certain features of our products may make it possible for others to manufacture and sell products with features identical or similar to ours, which could adversely affect our business.” · word for word

Off-label use and regulatory enforcement

“If the FDA or any foreign regulatory authorities determine that our promotional materials or training constitute promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions” · word for word

Revenue decline due to IV Solutions divestiture; core segments growing but overall top-line pressure.

“Revenue down 14.2% YoY; Vital Care segment down 58.1%.”

GAAP net loss persists, though improved from prior year.

“GAAP net loss $(15.7) million.”

Guidance implies modest recovery but adjusted EPS below prior year levels.

“FY2026 adjusted EPS guidance $7.75-8.45 vs $8.98 in FY2024.”

IV Solutions divestiture impact on revenue

“Vital Care includes $0.0 million and $126.5 million of IV Solutions revenue, respectively, as compared to $88.0 million and $268.7 million” · word for word

Ongoing warning letter and regulatory risks

“risks associated with the timing and resolution of the 2025 warning letter” · word for word

Quality remediation costs

“Quality remediation/recall $13,797 (thousands) for three months ended September 30, 2025 vs $7,737 (thousands) for three months ended September 30, 2024.”

Vital Care revenue decline

“Vital Care $77,992 (thousands) for three months ended September 30, 2025 vs $164,487 (thousands) for three months ended September 30, 2024.”

High leverage

“Long-term debt $1,313,931 (thousands) at September 30, 2025.”